Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
|Articles|December 8, 2003
Walgreens warns of Medi-Cal pullout
Walgreens threatened to pull its 356 pharmacies out of the California Medicaid program (Medi-Cal) if the state proceeds with a 5% reimbursement cut slated to begin on New Year's Day.
Advertisement
Advertisement
Related to this article
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
3
FDA Approves First Generic for Climara Pro Hormone Therapy Patch
4
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
5